Clinicians treating patients with antipsychotic medications have long attempted to optimize outcomes in their patients by adapting evidence from clinical trials to clinical practice settings (Stahl, 1999a) . However, there is little evidence to guide what to do when patients have poor responses. In such cases, many clinicians attempt innovative combinations of medicines. On the one hand, when such attempts are ahead of the evidence, such as combining agents with different mechanisms of action (e.g. mood stabilizers added to atypical antipsychotics), they can lead to hypothesisgenerating ideas that are confirmed with controlled trials (Casey et al., 2003) . On the other hand, when such attempts are beyond the evidence, such as combining two fundamentally similar antipsychotics together, they can lack theoretical foundation, generate misleading information, set into motion irrational prescribing habits, and create more costs than benefits for patients (Stahl, 1999b (Stahl, ,c, 2002a Stahl and Grady, In Press) . Suzuki et al. (2004) boldly explore a practice that is relatively unique to Japan yet fairly standard there, namely the use of multiple conventional antipsychotics in up to 90 % of psychotic patients. These investigators ask whether converting such patients to a single main antipsychotic is any less beneficial than the standard Japanese practice of conventionalconventional antipsychotic polypharmacy. It is remarkable given the lack of evidence for this practice that such an investigation has not been done previously. The authors found that most patients converted to monotherapy remained stable or improved, and suggest that many times polypharmacy with two conventional antipsychotics can be avoided.
Antipsychotic utilization in Japan
Potential rationales for conventional-conventional antipsychotic polypharmacy as well as some potential flaws with this approach are summarized in Table 1 . The findings of Suzuki et al. (2004) pointing out that many patients do at least as well on one main agent as on several, plus the possibility that multiple drugs may really be a form of too high dosing and thus cause dose-related and other complications, including premature death (Waddington et al., 1998 ) may provide the needed impetus for turning the tide against this particular practice in Japan.
Antipsychotic utilization worldwide
In other parts of the world, antipsychotic polypharmacy, but of a different type, is rapidly on the rise, yet this practice may also be equally lacking in convincing evidence or demonstrated benefits (Stahl, 1999b (Stahl, ,c, 2002a Stahl and Grady, In Press) . Thus, in Europe and North America, although prescribers do not frequently combine two conventional antipsychotics, they are more and more frequently combining an atypical antipsychotic either with a conventional antipsychotic or with a second atypical antipsychotic (Stahl and Grady, In Press ; Stahl et al., 2002a) . Given the popularity of conventional-conventional antipsychotic polypharmacy in Japan, it seems likely that as atypical antipsychotics are introduced into that country, atypical-conventional as well as atypicalatypical antipsychotic polypharmacy may become popular there also.
An international antipsychotic algorithm project under the leadership of Herbert Meltzer is currently attempting to incorporate worldwide perspectives on these practices into the hierarchy of treatment options for psychotic patients. Since the new atypical antipsychotics are far more expensive in the USA than in other countries, the current state of budgetary deficits by state governments who largely pay for these drugs is also causing serious evaluation of their use, especially the most expensive use of combining two atypical antipsychotics together .
Evidence-based prescribing or prescribing-based evidence ?
Given the widespread use of an atypical antipsychotic either with a conventional antipsychotic or with an atypical antipsychotic, it is amazing to see how little evidence or rationale there is upon which this practice is based. The evidence for combining an atypical antipsychotic with a conventional antipsychotic is almost absent, and the sum total of studies adding two atypical antipsychotics together is no controlled trial and only six reports totalling 12 cases, that show cumulatively no benefit and/or side-effects more often than benefits without additional sideeffects (Stahl and Grady, In Press ; Freudenreich and Goff, 2002) . The rationale for combining atypical antipsychotics with conventional antipsychotics as well as some of the potential flaws with this approach are also summarized in Table 1 . Although often useful in emergent situations and in-patient settings, most worrisome about combining a conventional antipsychotic with an atypical antipsychotic for the long term is that the conventional antipsychotic will sabotage the benefits of the atypical antipsychotic. Studies of such combinations are lacking but much needed. Table 1 also lists some of the rationales given by proponents of long-term atypical-atypical antipsychotic polypharmacy. Although no two atypical antipsychotics have identical pharmacological binding profiles at neurotransmitter receptors, the value of adding two agents together to exploit these pharmacological differences in order to gain a better clinical outcome seems to be much more expensive, less theoretically appealing and even less evidence-based compared to adding a mood-stabilizing agent acting at an ion channel with an atypical antipsychotic, for both bipolar disorder and schizophrenia (Casey et al., 2003 ; Stahl and Grady, In Press) .
If atypical-atypical antipsychotic polypharmacy is to be justified over monotherapy or augmentation with a mood stabilizer, controlled studies are desperately needed. The study of Suzuki et al. (2004) could serve as a model for investigating the utility of atypical-conventional and atypical-atypical antipsychotic polypharmacy. The lesson learned from Suzuki et al. is that the well-intentioned impulse to 'do something ' and not to 'un-do stabilized patients ' may not necessarily translate into improved clinical outcomes when medications are combined without either compelling evidence or a convincing theoretical basis. In the meantime and until such studies of antipsychotic polypharmacy are performed, it might be best to adapt this practice conservatively and only after treatment options with better evidence and lower costs are attempted first.
